The members of the Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) initiative proudly announced the recruitment of its first research participant today.
The first participant was recruited in Geneva, Switzerland, within the diagnostic and patient management sub-study (DMPS) of the AMYPAD project. In this clinical study, researchers aim to include subjects suspected of possible Alzheimer’s disease and determine the usefulness of β-amyloid imaging as a diagnostic marker for Alzheimer’s disease. The study will involve people with dementia, but also subjects with mild cognitive impairment (MCI) or subjective cognitive decline (SCD), and will study the impact of β-amyloid PET on both diagnostic confidence, patient management and resource utilisation.
According to Prof. Giovanni Frisoni (pictured), group leader of the laboratory of neuroimaging of aging at the University of Geneva, “Anyone would agree that amyloid PET accurately reflects brain amyloidosis, but to what extent this information addresses patients’ needs and expectations rather than physicians’ and industry’s is a contentious subject that AMYPAD DPMS will provide an answer to”.
The ambitious Europe-wide initiative aims to improve the understanding, diagnosis and management of Alzheimer’s Disease through the utilisation of β-amyloid PET imaging. The 5-year large-scale study involves 15 organisations including academic and industrial partners, SMEs and patient organisations, and it is funded by the IMI-2 program.
For further information, visit www.amypad.eu or please contact: email@example.com
The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.